"Designing Growth Strategies is in our DNA"

Protease Inhibitors Market Size, Share and Global Trend, By Disease Indication (HIV/AIDS,Hepatitis C,Alpha-1 Antitrypsin Deficiency,Hereditary Angioedema (HAE),Others), By Distribution Channel (Hospitals pharmacies,Retail pharmacies,Online pharmacies), and Geography Forecast till 2026

Region : | Report ID: FBI100464 | Status : Ongoing

 

KEY MARKET INSIGHTS

Protease inhibitors have extensive applications in disease prevention, there are many pharmaceutical & biotechnological companies and research institutions those are focusing on discovery of protease inhibitors as new therapeutic drugs. For instance, LEADING BIOSCIENCES INC, a pharmaceutical company has initiated phase 2 clinical trials for LB1148, a serine protease inhibitor to evaluate its efficacy in improving GI function in a patient undergoing major cardiovascular surgery. With the gained popularity and demand for use of protease inhibitors in HIV and hepatitis, there has been a significant rise in demand of protease inhibitors globally.

The growth in global protease inhibitors market is anticipated to be driven by the increased research for clinical application of protease inhibitors combined with the rise in demand of protease inhibitors in various fields. Moreover, the potential pipeline protease inhibitor products especially for HIV, are anticipated to fuel the global protease inhibitors market during the forecast period.

To gain extensive insights into the market, Request for Customization

However, the side effects and unbearable toxicity associated with the protease inhibitors are the factors that are likely to hamper the growth in global protease inhibitors market.

Key Players Covered

Some of the major companies that are present in the global protease inhibitors market are Merck KGaA, Boehringer Ingelheim International GmbH, AbbVie Inc., Bristol-Myers Squibb Company, Janssen Pharmaceutical Companies, GlaxoSmithKline plc, Vertex Pharmaceuticals Incorporated and other players.

Segmentation

Segmentation

 Details

By Disease Indication

·      HIV/AIDS

·      Hepatitis C

·      Alpha-1 Antitrypsin Deficiency

·      Hereditary Angioedema (HAE)

·      Others

By Distribution Channel

·      Hospitals pharmacies

·      Retail pharmacies

·      Online pharmacies

By Geography

·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

As of 2018, HIV/AIDS disease indication is anticipated to account for the highest share in the global protease inhibitor market owing to increasing prevalence of the disease.

Key Insights

  • Pipeline analysis
  • Prevalence of HIV/AIDS
  • Regulatory scenario for key countries
  • Key mergers and acquisitions

Regional Analysis

The global protease inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is expected to witness the highest growth in the protease inhibitors market during the forecast period owing to the increased clinical trials for HIV protease inhibitors and increased healthcare expenditure. According to the Centers for Disease Control and Prevention, approximately 38,500 new cases of HIV infection were added in 2015 in the U.S., which is likely to augment the growth in protease inhibitors market in North America. The protease inhibitors market is estimated to flourish in the Asia Pacific and Europe in the projected duration due to the advancements in health infrastructure and raising awareness about anti-retroviral therapy for HIV.

Key Industry Developments

  • In February 2018, AbbVie Inc. received the positive recommendation for MAVIRET by CADTH Canadian Drug Expert Committee (CDEC). MAVIRET is a therapy for chronic hepatitis C virus (HCV) infection containing NS3/4A protease inhibitor.
  • In January 2016, Merck & Co., Inc. received FDA approval for ZEPATIER, a drug manufactured using NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV)
  • In July 2018, Janssen Pharmaceutical Companies received U.S Food and Drug Administration (FDA)approval for the SYMTUZA, a protease inhibitor class of drug indicated for the treatment of HIV-1 Infection.

Protease Inhibitors Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2019
  • 2016-2018

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization

Healthcare Clients

Intuitive_Surgical_logo
Ge-Healthcare
Sedana-Cyan-Black-Tag
Logo_Merck_KGaA_2015
chong-kun-dang

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X